---
title: 'Head of Medical Affairs at Remix Therapeutics'
canonical: 'https://feeny.ai/job/head-of-medical-affairs-remix-therapeutics-watertown-x0b0ddpp9nnc'
type: 'job'
last_seen: '2026-10-24'
---

# Head of Medical Affairs at Remix Therapeutics

- **Company:** Remix Therapeutics
- **Location:** Watertown, MA
- **Posted:** 2026-09-25
- **Last confirmed live:** 2026-10-24
- **Apply:** https://job-boards.greenhouse.io/remixtherapeutics/jobs/4738108005

## Job description

Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.

Position Summary:

Remix is seeking a Head of Medical Affairs to provide medical affairs leadership for REM-422 and contribute to the development of future programs across the portfolio. REM-422 is an innovative investigational therapy targeting RNA splicing machinery, with adenoid cystic carcinoma (ACC), a rare salivary gland cancer, as its first clinical indication. With no approved therapy for ACC, this is an opportunity to help shape the medical and treatment landscape for patients with a rare cancer while playing a key role in advancing a novel therapeutic approach.

Reporting directly to the Chief Medical Officer and based at our Watertown, MA headquarters, this individual will play a central role in disease education, scientific leadership, external engagement, evidence generation and trial execution, and interpretation of emerging clinical data. This is the first medical affairs hire at Remix. You will define what the function is, hire the people who follow you, and grow the organization as REM-422 moves toward approval and launch.  You will also be the external scientific voice of the company, personally engaged in the field with KOLs and advocacy leaders. The role is global in scope; however, the United States is the initial focus and the first launch market.

Key Responsibilities:

Disease Education and Market Definition

- Lead development and execution of Medical Strategy with a focus on REM-422 for use in ACC.
- Build scientific awareness of ACC as a MYB driven disease across medical oncology, head and neck, and ENT communities, and establish Remix as a credible scientific voice in the field.
- Work with other key stakeholders to map the ACC patient journey: where patients present, who they see, how they are referred, and where they fall out of the system.
- Advance understanding of MYB biomarker testing so eligible patients can be identified, partnering with Clinical Development, Regulatory, and diagnostic partners.
- Generate and codify real world insight on current management patterns and unmet need and feed it into development and launch planning.

Scientific Leadership and External Engagement

- Personally engage leading ACC, head and neck, and hematology investigators, and build the KOL network.
- Oversee advisory boards, congress strategy, and scientific exchange that shape how ACC is defined and treated.
- Build durable partnerships with ACC advocacy organizations and bring the patient's voice into development and launch decisions.
- Represent Remix externally in scientific and business development settings.

Evidence Generation and Communication

- Own publication strategy and execution across ACC and AML/HR-MDS.
- Direct the HEOR, natural history, burden of disease, and real-world evidence to work that a disease with no approved therapy leaves undone.
- Run the investigator sponsored trial program and provide medical insight into company sponsored trial design, endpoints, and lifecycle strategy.

Launch Readiness and Cross-Functional Partnership

- Partner with Clinical Development, Regulatory, and Commercial on launch preparation, contributing to the medical and scientific perspective.
- Ensure the clinical evidence base is accurately understood across the organization so that planning rests on what the data actually supports.
- Provide an independent medical review of educational and promotional material and set the standard for scientific accuracy.
- Coordinate field medical planning with commercial field planning, so coverage is complementary, and we act as one Remix team in all external interactions.
- Inform market access strategy through the burden of disease and health economics evidence.

Building the Function

- Design and stand-up field medical, medical information, and medical communications, making clear build versus outsource decisions and owning the budget.
- Hire and lead a small, seasoned team that operates ahead of its headcount, and set the plan for how the function scales through approval and into launch.
- Establish medical affairs policies, SOPs, and review processes consistent with the principles of scientific engagement, and partner with Legal and Compliance to keep all activity within Remix policy and applicable law.
- Own the medical governance of expanded access and compassionate use requests, and the escalation pathway between medical information and Pharmacovigilance.

Qualifications:

- Advanced life science degree required. MD or equivalent medical degree preferred; PhD or PharmD considered.
- 10+ years in medical affairs and prior leadership of the function.
- Oncology experience is required. Solid tumors strongly preferred; head and neck or salivary gland is a distinct advantage.
- Built a Medical Affairs function from an early state rather than only running an established one.
- Launch experience preferred, ideally with a first in class or first in disease product where the treatment pathway had to be established.
- Existing relationships across oncology academic institutions.
- Global perspective preferred, including working knowledge of the European medical affairs and regulatory environment or experience supporting ex-US capability.
- Excellent written and verbal communication skills, including experience authoring or reviewing scientific and medical content for external audiences.
- Demonstrated ability to operate effectively in a highly collaborative, cross-functional, and fast-paced biotechnology environment.

Salary Range

$293,000 - $415,000 USD

This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable.  Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

## About Remix Therapeutics

## Company Overview
- **One-liner**: Clinical-stage biotechnology company developing first-in-class oral small molecule therapies that reprogram RNA processing to address previously undruggable drivers of cancer and other diseases.
- **Entity Type**: Private (Venture-backed; merged with Passage Bio in June 2026 with a concurrent $100M private placement)
- **Headquarters**: Watertown, Massachusetts, United States
- **Founded**: 2018
- **Founders**: Peter Smith, PhD

## Core Business
- **Primary industry**: Biotechnology – RNA-targeted therapeutics, oncology
- **Target customers**: B2B (pharmaceutical partners like Roche and Johnson & Johnson) and B2C (patients with high-unmet-need cancers, served through healthcare providers)
- **Mission or purpose statement**: “Reprogramming RNA to transform patients’ lives” – focused on modulating RNA processing to address disease drivers at their origin

## Products & Services
- **REM‑422**: First-in-class, orally available small molecule mRNA degrader targeting the historically undruggable transcription factor MYB. Currently in Phase 1 clinical trials for acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR‑MDS), and adenoid cystic carcinoma (ACC). Granted FDA Fast Track designation for ACC.
- **REMaster™ Drug Discovery Platform**: Proprietary platform that designs small molecules to harness cellular RNA‑processing machinery, enabling modulation of gene expression for targets previously considered intractable. Used for internal pipeline and partnered programs.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed (private company; post-merger valuation unknown)
- **Key Metric**: Total funding ~$240.7M (including a $100M private placement concurrent with the Passage Bio merger in June 2026). Annual revenue (2025 estimate): $3.2M (typical for a clinical‑stage biotech).
- **Notable Investors/Partners**:  
  - Investors: Surveyor Capital (Series B lead, $70M), Foresite Capital (Series A lead, $65M), The Column Group (Venture Round lead, $60M)  
  - Partners: Roche (collaboration for RNA‑processing modulators), Johnson & Johnson Innovative Medicine (multi‑year, three‑target oncology/immunology collaboration)  
- **Growth Signals**:  
  - Preliminary Phase 1 data for REM‑422 showed strong anti‑tumor activity and favorable safety in ACC  
  - FDA Fast Track designation for REM‑422 in ACC  
  - Merger with Passage Bio (June 2026) brings additional capital and pipeline synergies  
  - Active job postings up 200% month‑over‑month and quarter‑over‑quarter  
  - Headcount of 49 employees with a heavy concentration in research (43%)

## Competitive Advantages
- **Proprietary REMaster platform** uniquely enables oral small‑molecule modulation of RNA processing, expanding the druggable target space beyond traditional protein inhibition
- **First‑in‑class oral MYB mRNA degrader** (REM‑422) addresses a transcription factor long considered undruggable
- **Top‑tier pharma collaborations** with Roche and J&J validate the technology and provide non‑dilutive funding
- **Strong scientific leadership** (CEO/co‑founder Peter Smith, PhD, formerly CSO at H3 Biomedicine, where he advanced three molecules to the clinic)

## Strategic Focus
- Advance REM‑422 through Phase 1 trials across multiple MYB‑driven cancers (AML, HR‑MDS, ACC) and expand into additional solid tumors
- Leverage the REMaster platform to discover new RNA‑processing modulators for oncology and immunology
- Deepen existing pharma partnerships and seek new collaborations to accelerate pipeline growth
- Integrate the recently merged Passage Bio assets and utilize the $100M private placement to fund clinical development

## Why Work Here
- **Culture**: Values-driven environment centered on “True to Our RNA” (scientific integrity), “Courageous Curiosity” (bold innovation), and “Remixing Together” (collaboration and mutual support). Employees describe a flat, science‑first culture where diverse perspectives are welcomed.
- **Work model**: Hybrid? While not explicitly stated, the company has three offices in the Boston area (Watertown HQ, One Kendall Square Cambridge, and another Cambridge location). Lab‑based roles are likely on‑site; corporate roles may offer flexibility.
- **Perks & environment**: Small company (~49 people) with the energy of a startup but backed by significant funding and pharma partnerships. Employees share a strong sense of mission to bring new therapies to patients with few options. “We take our work seriously but not ourselves.”
- **Growth opportunity**: Rapidly advancing clinical pipeline and post‑merger expansion offer career advancement in a high‑visibility biotech. Recent ramp‑up in hiring (3 active postings for senior leadership roles like VP of Program Team Lead, VP of Biostatistics, and Senior Manager of Strategy & BD) signals scaling.

## Sources
1. [Remix Therapeutics Home](https://www.remixtx.com/)
2. [Remix Therapeutics About Us](https://www.remixtx.com/about/)
3. [Remix Therapeutics Join Us](https://www.remixtx.com/join/)
4. [Remix Therapeutics LinkedIn](https://www.linkedin.com/company/remix-therapeutics)
5. [Remix Therapeutics Greenhouse Careers](https://job-boards.greenhouse.io/remixtherapeutics)

## Other roles at Remix Therapeutics

- [Senior Director, GCP Quality](https://feeny.ai/job/senior-director-gcp-quality-remix-therapeutics-watertown-ancn66bxrnf3) — Watertown, MA
- [Associate Director, Clinical Data Management](https://feeny.ai/job/associate-director-clinical-data-management-remix-therapeutics-watertown-qq070g410ywh) — Watertown, MA
- [Vice President/Senior Director, Nonclinical Drug Safety & Toxicology](https://feeny.ai/job/vice-president-senior-director-nonclinical-drug-safety-toxicology-remix-hcv58wta0q0b) — Watertown, MA
- [Vice President, Clinical Development](https://feeny.ai/job/vice-president-clinical-development-remix-therapeutics-watertown-0ewyfa0bvx9g) — Watertown, MA
- [Head of Medical Affairs](https://feeny.ai/job/head-of-medical-affairs-kardigan-princeton-rq45s28mr31y) — Princeton, NJ